関連する実験動画
Updated: Sep 9, 2025

12:43
On-Chip Endothelial Inflammatory Phenotyping
Published on: July 21, 2012
11.0K
サイトカインストームとマイクロ血管の運命:血栓性マイクロ血管病における内皮損傷に関する機械的洞察
1Department of Biomedical and Laboratory Science, Africa University, Mutare, Zimbabwe.
Annals of medicine and surgery (2012)
|September 3, 2025
まとめ
トロンボティック・マイクロ血管病 (TMA) は,サイトカインの調節不良によって引き起こされる内皮機能障害を伴う. これらの炎症反応はTMAの進行を増幅し,血管の炎症を疾患の重症性の重要な要因として強調します.
科学分野:
- 血管生物学
- 免疫学
- 血液学
背景:
- 血栓性微血管病 (TMA) は,マイクロ血管血栓症,低血小板数,臓器損傷によって特徴づけられる疾患群である.
- 内皮機能不全は,異なるTMAタイプに共通する根本的なメカニズムです.
- サイトカインの調節不全は,TMAにおける血管損傷の開始と持続に重要な役割を果たします.
研究 の 目的:
- 血栓性微血管病変の病原性における サイトカイン不調の役割を調査する.
- 炎症性サイトカインがTMAにおける内皮活性化と血栓形成にどのように寄与するかを理解する.
- TMAサブタイプの文脈における血管炎症の重要性を強調する.
主な方法:
- TMAの病原性を理解する最近の進歩のレビュー.
- 内皮活性化におけるプロ炎症性サイトカイン (TNF-α,IL-1β,IL-6) の役割の分析
- 様々なTMAサブタイプ (aHUS,TTP,二次TMA) のサイトカインプロフィールの検査
主要な成果:
- 炎症誘発性サイトカインは,白血球の粘着と前血栓状態を促す,持続的な内皮活性化を誘発する.
- サイトカインの反応は,原発的 (例えば,aHUS,TTP) と二次的なTMAの両方の進行に関与しています.
- サイトカイン濃度の上昇は,TMAにおける内皮損傷と臨床的重症と相関する.
結論:
- サイトカインの調節不全は,血栓性マイクロ血管病変の統合的病原性因子である.
- TMAの炎症シグネチャーの理解は,内皮機能障害と血管損傷の管理に不可欠です.
- TMAは,全身血管炎のより広い文脈で見るべきです.
関連する概念動画
Inflammation
55.1K
Overview
55.1K
Intracellular Signaling Affects Focal Adhesions
2.8K
Integrins act both as extracellular input receivers and as intracellular processing activators. As their name suggests, integrins are entirely integrated into the membrane structure. Their hydrophobic membrane-spanning regions interact with the phospholipid bilayer's hydrophobic region. These membrane receptors provide extracellular attachment sites for effectors like hormones and growth factors. They activate intracellular response cascades when their effectors are bound and active.
Some...
Some...
2.8K
Extrinsic and Intrinsic Pathways of Hemostasis
9.2K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
9.2K
Mechanism of Angiogenesis
5.8K
Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
5.8K
Clot Retraction and Fibrinolysis
6.8K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
6.8K
Regulation of Angiogenesis and Blood Supply
2.7K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.7K

